Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A-M Laberge

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Public Health Genomics|April 17, 2010
Debating clinical utilityWylie Burke, A-M Laberge, N Press
Public Health Genomics|October 30, 2009
Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemiaA-M Laberge, C Watts, K Porter, et al.
Public Health Genomics|July 8, 2011
Genetics in health care: an overview of current and emerging modelsR N Battista, I Blancquaert, A-M Laberge, et al.
International Journal of Peptide and Protein Research|January 1, 1995
Structural characterizations of neuropeptide tyrosine (NPY) and its agonist analog [Ahx5-17]NPY by NMR and molecular modelingY Boulanger, Y Chen, F Commodari, et al.
Clinical Genetics|September 7, 2005
Population history and its impact on medical genetics in QuebecA-M Laberge, J Michaud, A Richter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2013
Cost effectiveness of newborn screening for cystic fibrosis: a simulation studyL Nshimyumukiza, A Bois, P Daigneault, et al.
European Journal of Human Genetics : EJHG|November 30, 2017
Points to consider for laboratories reporting results from diagnostic genomic sequencingD F Vears, K Sénécal, A J Clarke, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Public Health Genomics|April 17, 2010
Debating clinical utilityWylie Burke, A-M Laberge, N Press
Public Health Genomics|October 30, 2009
Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemiaA-M Laberge, C Watts, K Porter, et al.
Public Health Genomics|July 8, 2011
Genetics in health care: an overview of current and emerging modelsR N Battista, I Blancquaert, A-M Laberge, et al.
International Journal of Peptide and Protein Research|January 1, 1995
Structural characterizations of neuropeptide tyrosine (NPY) and its agonist analog [Ahx5-17]NPY by NMR and molecular modelingY Boulanger, Y Chen, F Commodari, et al.
Clinical Genetics|September 7, 2005
Population history and its impact on medical genetics in QuebecA-M Laberge, J Michaud, A Richter, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 19, 2013
Cost effectiveness of newborn screening for cystic fibrosis: a simulation studyL Nshimyumukiza, A Bois, P Daigneault, et al.
European Journal of Human Genetics : EJHG|November 30, 2017
Points to consider for laboratories reporting results from diagnostic genomic sequencingD F Vears, K Sénécal, A J Clarke, et al.
Pageof 1